Aldosterone as a Determinant of Cardiovascular and Renal Dysfunction

Foster R.H. , MacFarlane C.H. , Bustamante M.O. Recent progress in understanding aldosterone secretion. Gen Pharmacol 1997; 28: 647–51

Fuller P.J. Aldosterone's effects and mechanism of action. Curr Opin Endocrinol Diabetes 1997; 4: 218–24

Luetscher J.A. Jr. , Neher J.P. , Wettstein A. Isolation of crystalline aldosterone from the urine of a nephrotic patient. Experientia 1954; 10: 456–8

Edelman I.S. , Fimognari G.M. On the biochemical mechanism of action of aldosterone. Rec Prog Horm Res 1968; 24: 1–44

Rossier B.C. Mechanisms of action of mineralocorticoid hormones. Endocr Res 1989; 15: 206–26

Duprez D. , De Buyzere M. , Rietzchel E.R. , Clement D.L. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2: 327–34

Pitt B. , Zannad F. , Remme W.J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17

Rocha R. , Chander P.N. , Zuckerman A. , Stier C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232–7

Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertension 2001; 19: 829–42

Wehling M. Non-genomic actions of steroid hormones. Trends Endocrinol Metab 1994; 5: 347–53

Wehling M. , Spes C.H. , Win N. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517–22

Christ M. , Douwes K. , Eisen C. Rapid non-genomic effects of aldosterone on sodium transport in rat vascular smooth muscle cells: involvement of the Na+/H+ antiport. Hypertension 1995; 25: 117–23

Wehling M. , Neylon C.B. , Fullerton M. Non-genomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res 1995; 76: 973–9

Wehling M. Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. J Mol Med 1995; 73: 439–47

Ebata S. , Muto S. , Okada K. Aldosterone activates Na+/H+ exchange in vascular smooth muscle cells by non-genomic and genomic mechanisms. Kidney Int 1999; 56: 1400–12

Young M. , Fullerton M. , Dilley R. , Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93: 2578–83

Bonvalet J.P. , Alfaidy N. , Farman N. , Lombes M. Aldosterone: intracellular receptors in human heart. Eur Heart J 1995; 16(suppl N): 92–7

Kornel L. Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7: 100–3

Lombes M. , Oblin M.E. , Gasc J.M. , Baulieu E.E. , Farman N. , Bonvalet J.P. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71: 503–10

Farquharson C.A.J. , Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594–7

Conn J.W. , Knopf R.F. , Nesbit R.M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159–72

Nishimura M. , Uzu T. , Fujii T. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261–6

Meyer T.W. , Anderson S. , Rennke H.G. , Brenner B.M. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 1987; 31: 752–9

Lewis E.J. , Hunsicker L.G. , Bain R.P. , Rohde R.D. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–62

Remuzzi G. , Ruggenenti P. , Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2–15

The GISEN Study Group. Randomized placebo-controlled trial of effect of ramipril on decline in GFR and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group. Lancet 1997; 349: 1857–63

Ruggenenti P. , Perna A. , Gherardi G. , Gasdpari F. , Benini R. , Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiolgici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252–6

Greene E. , Kren S. , Hostetter T.H. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063–8

Quan Z.Y. , Walser M. , Hill G.S. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41: 326–33

Gavras H. , Brunner H.R. , Laragh J.H. Malignant hypertension resulting from deoxycortisone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 1975; 36: 300–9

Rocha R. , Chander P.N. , Khanna K. , Zuckerman A. , Stier C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451–8

Rocha R. , Chander P.N. , Zuckerman A. , Stier C.R. Jr. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats [Abstract]. Hypertension 1998; 32: 598

Brown N.J. , Kim K.S. , Chen Y.Q. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336–44

Brown N.J. , Nakamura S. , Ma L. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219–27

Sun Y. , Zhang J. , Zhang J.Q. , Ramires F.J. Local angiotensin II and transforming growth factor-beta 1 in renal fibrosis of rats. Hypertension 2000; 35: 1078–84

Stier C Jr. , Zuckerman A. , Harashima H. , Chander P. Antioxidants reduce aldosterone-induced renal vascular injury in stroke-prone spontaneously hypertensive rats [Abstract P4.03] Proceedings of the International Society of Hypertension, Chicago, 23 August, 2000

Schiffrin E.L. , Franks D.J. , Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 1985; 63: 1522–7

Brilla C.G. , Matsubara L.S. , Weber K.T. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A–16A

Weber K.T. , Anversa P. , Armstrong P.W. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992; 20: 3–16

Brown N.J. , Agirbasli M.A. Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-I. Hypertension 1998; 32: 965–71

Mantero F. , Opocher G. , Rocco S. , Carpene G. , Armanini D. Long-term treatment of mineralocorticoid excess syndromes. Steroids 1995; 60: 81–6

Jeunemaitre X. , Chatellier G. , Kreft-Jais C. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820–5

de Gasparo M. , Whitebread S.E. , Preiswerk G. , Jeunemaitre X. , Corvol P. , Menard J. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989; 32: 223–7

Helfer E.L. , Miller J.L. , Rose L.I. Side-effects of spironolactone therapy in the hirsute woman. J Clin Endocrin Metab 1988; 66: 208–11

Hughes B.R. , Cunliffe W.J. Tolerance of spironolactone. Br J Dermatol 1988; 118: 687–91

Epstein M. , Alexander J.C. , Roniker B. Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension [abstract]. Hypertension 1999; 33: 1075

Rabasseda X. , Silvestre J. , Castañer J. Eplerenone. Drugs Future 1999; 24: 488–501

Hasan F. , Weinberg E.O. , Delyani J. Aldosterone and cardiac hypertrophy: effects of eplerenone on LV function and hypertrophic remodeling in LV pressure overload [Abstract]. Circulation 1999; 100(suppl I): 1565

Pitt B. , Williams G. , Remme W. The EPHESUS Trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction (Eplerenone's Neurohormonal Efficacy and Survival Study) (In press)